Orchestra BioMed Holdings, Inc. OBIO

5.95 0.00 0.00% as of 25 Sep
Market cap
$366.0M
P/E
0.0×
Insider Buys alert about insiders buying in the last 12 month
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 0.00 0.00 0.00 — — — —
P/S ratio
5.92 55.83 105.69 42.60 — — — —
P/FCF ratio
0.00 0.00 0.00 0.00 — — — —
P/Operating CF
(87.29) (10.88) (26.58) (17.21) — — — —
P/B ratio
3.70 4.47 4.29 2.86 — — — —
Price to Tangible BV
3.70 4.47 4.29 2.86 — — — —
EV/Sales
3.16 35.92 74.36 21.57 — — — —
EV/EBITDA
0.00 0.00 0.00 0.00 — — — —
EV/Operating CF
(2.16) (1.87) (4.45) (2.60) — — — —
EV/FCF
(2.14) (1.86) (4.44) (2.55) — — — —
Quick Ratio
6.37 4.13 7.82 4.52 10.60 17.03 — —
Current Ratio
6.45 4.27 7.95 4.56 10.88 18.06 — —
Net Debt/EBITDA
1.80 0.82 1.71 2.30 4.44 11.26 — —
Debt/Assets
12.42% 18.76% 0.00% 9.93% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.27 0.43 0.00 0.18 0.00 0.00 — —
Asset Turnover
0.35 0.03 0.03 0.03 0.00 0.00 0.00 —
Operating CF/Net income
0.92 0.83 0.94 0.87 0.72 1.49 — —
Capex/Depreciation
(0.90) (0.85) (0.20) (1.54) — — — —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 — —
ROE
(122.40%) (120.84%) (81.47%) (138.33%) 10.09% 4.62% — —
ROA
(55.44%) (71.21%) (51.49%) (26.11%) (0.23%) (0.21%) 0.00% —
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% — —
Return on Tangible Assets
(57.01%) (112.28%) (62.03%) (49.71%) (23.16%) (8.55%) — —
Average Days of Receivables
1.04 12.73 13.09 9.92 — — — —
Research and Development Expense of Revenue
173.78% 1,622.59% 1,225.43% 621.14% — — — —
Selling, General and Administrative Expense of Revenue
80.38% 907.16% 733.99% 397.23% 0.00% 0.00% — —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
35.77% 402.39% 276.27% 96.60% — — — —
Graham Net Nets
0.24 0.18 0.21 0.28 — — — —
Graham Number
0.00 0.00 0.00 0.00 — — — —
Earnings Yield
(27.23%) (41.75%) (17.08%) (22.33%) — — — —
Free Cash Flow Yield
(24.96%) (34.52%) (15.84%) (19.86%) — — — —
Revenue per Share
0.70 0.07 0.08 0.24 0.00 0.00 — —
Operating CF per Share
(1.03) (1.37) (1.39) (1.95) (0.01) (0.02) — —
Capex per Share
(0.01) (0.01) 0.00 (0.04) 0.00 0.00 — —
Free Cash Flow per Share
(1.04) (1.38) (1.39) (1.99) (0.01) (0.02) — —
Cash per Share
2.23 1.81 2.64 5.59 0.09 0.13 — —
Shareholders Equity per Share
1.12 0.90 2.05 3.50 (0.19) (0.23) — —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 — —
Book value per Share
1.12 0.90 2.05 3.50 (0.19) (0.23) — —
Free Cash Flow
(49.45) (50.85) (46.20) (29.88) (0.27) (0.26) — —
Working Capital
91.18 52.96 77.91 66.12 1.64 2.03 — —
Capital Expenditures
(0.49) (0.29) (0.08) (0.59) — — — —
Net Current Asset Value
46.62 25.96 61.95 41.65 (163.96) (163.57) — —
EV/EBIT
0.00 0.00 0.00 0.00 — — — —
Capex to Sales
0.01 0.11 0.03 0.17 — — — —
Net Profit Margin
(158.16%) (2,313.27%) (1,779.71%) (951.26%) 0.00% 0.00% — —
Price to Operating Income
0.00 0.00 0.00 0.00 — — — —
Other line items
Depreciation/Fixed assets
0.32 0.24 0.31 0.26 — — — —
Cash ROIC
(29.07%) (45.54%) (30.46%) (21.11%) 12.45% 16.83% — —
Accounts Receivable Turnover
358.10 27.62 28.31 0.00 — — — —
Accounts Payable Turnover
0.03 0.05 0.05 0.11 0.00 0.00 — —
Inventory Turnover
0.79 1.28 0.88 0.00 — — — —
Average Days of Payables
11,708.82 9,185.83 5,690.86 6,864.08 0.00 0.00 — —
Days of Inventory on Hand
595.53 309.53 286.51 477.44 — — — —
Average Receivables
0.09 0.10 0.10 — — — — —
Average Payables
5.61 4.02 3.43 1.98 0.01 0.01 — —
Average Inventory
0.24 0.16 0.21 — — — — —
Average Assets
95.52 85.69 95.39 128.70 161.99 81.08 0.00 —
Average Common Equity
43.26 50.50 60.29 24.30 (3.75) (3.75) — —

Fold the line items

Columns are period end dates